Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KD103
- Development stage
- Preclinical
- Lead developer
- Kwang Dong Pharmaceutical
- Modality
- Small Molecules
01
Overview
KD103 is an experimental drug candidate being developed by Kwang Dong Pharmaceutical in collaboration with Seoul National University for the treatment of Alzheimer's disease. Currently in the preclinical stage, KD103 is a multi-target therapeutic agent designed to address the complex pathology of the disease. It is reported to function by inhibiting the aggregation of amyloid-beta and tau proteins, which are hallmark features of Alzheimer's neurodegeneration. The technology for KD103 was licensed from Seoul National University to expand Kwang Dong's central nervous system (CNS) research and development pipeline.
Beyond the preview
Go deeper on KD103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KD103.